PET Study of Breast Cancer Patients Using [68Ga]ABY-025
An Exploratory Study to Evaluate [68Ga]ABY-025 for PET Imaging of HER2 Expression in Subjects With Metastatic Breast Cancer
  • Phase

    Phase 1/Phase 2
  • Study Type

  • Status

    Completed No Results Posted
  • Study Participants

The study will evaluate [68Ga]ABY-025 for PET imaging of HER2 expression in subjects with HER2-positive or HER2-negative breast cancer.
Open-labeled, exploratory, single center study.

Group 1 (dose-finding) Six subjects with HER2-positive primary tumor status and four subjects with HER2-negative status. [68Ga]ABY-025 PET with low dose (100 μg) of ABY-025 peptide is performed, followed by a repeated PET within three weeks using high dose (500 μg) ABY-025 peptide (radioactivity maximum 500 MBq). A third [68Ga]ABY-025 PET will be performed in the HER2-positive subgroup only, when signs of progressive disease are found at routine clinical evaluation or else latest after 12 months regardless of disease status, then using the ABY-025 peptide dose previously determined to be preferable.
Group 2 Ten subjects with HER2-positive primary tumor status. [68Ga]ABY-025 PET is performed using the ABY-025 peptide dose determined to be preferable during the dose-finding part of the study, followed by a second [68Ga]ABY-025 PET investigation at signs of progressive disease or else latest after 9 months.
Study Started
Apr 30
Primary Completion
Jun 30
Study Completion
Jun 30
Last Update
Jan 13

Drug [68Ga]ABY-025

Intravenous injection followed by PET imaging

[68Ga]ABY-025 Experimental


Inclusion Criteria:

Subject is > 18 years of age
Diagnosis of invasive breast cancer with metastases

Availability of results from HER2 status previously determined on material from the primary tumor, either

HER2-positive, defined as a DAKO HercepTest™ score of 3+ or FISH positive or
HER2-negative, defined as a DAKO HercepTest™ score of 0 or 1+ or else; if 2+ then FISH negative
Volumetrically quantifiable metastasis lesions on CT or MRI, with at least one lesion >= 10 mm in smallest diameter and suitable for biopsy
ECOG performance status of =< 2
Life expectancy of at least 12 weeks

Hematological, liver and renal function test results within the following limits:

White blood cell count: > 2.0 x 10^9/L Haemoglobin: > 80 g/L Platelets: > 50.0 x 10^9/L ALT, ALP, AST: =< 5.0 times Upper Limit of Normal Bilirubin =< 2.0 times Upper Limit of Normal Serum creatinine: Within Normal Limits or else normal clearance

A negative pregnancy test (serum beta-human chorionic gonadotropin, beta-HCG) at screening for all female patients of childbearing potential, who must use a medically acceptable form of contraception from study start until at least 30 days after study termination
Subject is able to participate in the diagnostic investigations to be performed in the study
Informed consent

Exclusion Criteria:

Manifest second, non-breast malignancy
Known HIV positive or chronically active hepatitis B or C
Administration of other investigational medicinal product within 30 days of screening
Ongoing toxicity > grade 2 from previous standard or investigational therapies, according to US National Cancer Institute's "Common Terminology Criteria for Adverse Events v4.0 [CTCAE]"
Other ongoing severe disease that may influence the patient's ability to participate in the study
Pregnant or breast-feeding
No Results Posted